Grafton Bone Graft Recall: When Donor Screening Raises Questions After Processing

1 day ago

2 min read

What happens when a bone graft passes finished-product sterility testing, but a later donor-record review identifies a concern?

That's the issue behind a 2026 Medtronic recall involving certain Grafton demineralized bone matrix products.

What Happened?

Medtronic initiated a recall on August 12, 2026, involving specific Grafton Orthoblend and Grafton Paste products.

The FDA posted the Class II recall records on October 9.

According to the FDA, a donor-record review found that tissue associated with Medtronic batch A62881 did not meet all donor eligibility requirements related to microbial organisms.

The donor tissue had tested positive for Clostridium butyricum.

The tissue underwent gamma irradiation, and the finished product passed sterility testing.

However, Medtronic determined that unused products from the affected donor tissue should be retrieved because a potential infection concern remained.

Why It Matters to Surgical Professionals

Bone graft materials are part of many surgical specialties, particularly orthopedic and spine procedures.

They also introduce a unique supply-chain consideration.

Unlike many manufactured devices, human-derived tissue products depend on donor screening, tissue processing, product testing, and traceability.

A concern discovered in donor documentation can therefore become relevant even after processing and finished-product testing.

This recall demonstrates why no single checkpoint tells the entire quality story.

A product can pass one quality assessment while another part of its eligibility review raises a separate concern.

The OR and Supply-Chain Connection

The recall instructed customers to identify and quarantine unused affected products, arrange returns, and communicate the notice throughout their organizations.

For products that had already been implanted, the manufacturer's notice included information for clinicians evaluating possible infection concerns.

For surgical professionals, the operational lesson centers on traceability.

Can an organization identify which graft products it received?

Can it distinguish affected from unaffected inventory?

Can it connect relevant product information to its documentation and appropriate clinical follow-up processes?

Those are important questions for tissue tracking and recall readiness.

The FTLOS Takeaway

Patient safety doesn't begin when the graft reaches the sterile field.

It begins with the systems responsible for donor eligibility, processing, testing, distribution, and traceability.

And when a concern emerges, reliable communication helps organizations respond.

Join the Conversation

For surgical technologists, tissue coordinators, and perioperative leaders:

What makes tissue-product traceability effective in your organization?

U.S. Food and Drug Administration. “Class 2 Device Recall Grafton Orthoblend (Product T44150) and Grafton Paste (Product T45005).” FDA Medical Device Recalls, 9 Oct. 2026, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=222236.